1 Röllig C,Knop S,Bornhäuser M. Multiple myeloma[J]. Lancet,2015,385(9983):2197-2208. 2 Fujino M.The histopathology of myeloma in the bone marrow[J]. J Clin Exp Hematop,2018,58(2):61-67. 3 Shi H,Chen Z,Xie J,et al. The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China[J]. Kidney Dis (Basel),2016, 1(4):235-240. 4 Lyubimova N V,Timofeev Y S,Abaev V M,et al.Immunochemical Diagnosis of Multiple Myeloma[J]. Bull ExpBiol Med,2018,165(1):84-87. 5 Delgado-Calle J,Bellido T,Roodman G D. Role of osteocytes in multiple myeloma bone disease[J].CurrOpin Support Palliat Care,2014,8(4):407-413. 6 翟洪顺,张佳仕,邹德学,等. 44例多发性骨髓瘤实验室指标及Ig 类型改变的分析[J].北华大学学报,2012,13(2):176-179. 7 Lyubimova N V,Timofeev Y S,Abaev V M,et al. Immunochemical Diagnosis of Multiple Myeloma[J]. Bull Exp Biol Med,2018,165(1):84-87. 8 Fernández de Larrea C,Isola I,Pereira A,et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression[J]. Leukemia, 2018,32(6):1427-1434. 9 Barnidge D R,Tschumper R C,Theis J D,et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS[J]. J Proteome Res,2014,13(4):1905-1910. 10 Kozuru M,Uike N,Takahira H,et al.Immunoglobulin class switch from IgA1 to IgG2 and simultaneous association with Bence Jones proteinuria in the escape phase in a myeloma patient treated with interferon alpha[J]. Br J Haematol,1997,98(2):114-118. 11 范纯武,赵锐,多发性骨髓瘤病程中IgA型转变为IgG型一例[J]. 中华血液学杂志,1998,5(19):240. 12 蔺丽慧,吕娟芬,李莉. 多发性骨髓瘤M蛋白转型1例报告[J]. 第二军医大学学报,2009,30(2):231-232. |